Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1NSCLC 1Myelodysplastic Syndromes 1Mucopolysaccharidosis I 1Metastatic Castration-resistant Prostate Cancer 1Metabolism, Inborn Errors 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hemoglobinopathies 1Graft vs Host Disease 1Disease Progression 1

Interventions

Pemetrexed 14Carboplatin 13osimertinib 11aflutinib 9Drug Therapy 9Gefitinib 8Radiotherapy 6Docetaxel 6Cisplatin 6pembrolizumab 5anlotinib 5Radiosurgery 5Paclitaxel 5icotinib 4Vinorelbine 4Gemcitabine 4Erlotinib Hydrochloride 4tislelizumab 3camrelizumab 3apatinib 3HM781-36B 3toripalimab 2spartalizumab 2rezivertinib 2dacomitinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC × Clinical Trials, Phase I as Topic × Clear all
NCT04402008 2024-06-25

Study of Poziotinib in Japanese Patients With NSCLC

Spectrum Pharmaceuticals, Inc

Phase 1/2 Terminated
42 enrolled 16 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡